Compare RVT & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVT | IMNM |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | N/A | 2020 |
| Metric | RVT | IMNM |
|---|---|---|
| Price | $17.35 | $22.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.22 |
| AVG Volume (30 Days) | 243.4K | ★ 2.5M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.95 | N/A |
| Revenue | N/A | ★ $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.53 |
| P/E Ratio | $4.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.85 | $5.15 |
| 52 Week High | $14.93 | $25.30 |
| Indicator | RVT | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 73.97 | 60.67 |
| Support Level | $16.95 | $20.05 |
| Resistance Level | $17.20 | $22.01 |
| Average True Range (ATR) | 0.20 | 1.28 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 99.28 | 82.00 |
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements. The company invests in Industrials, Financials, Information Technology, Materials, Health Care, Communication Services, Real Estate and others.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.